Clinical trials in Dijon – page 3

819 clinical trials in Dijon, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Dijon at a glance

819

clinical trials

Research sites2

Quick filters

819 trials in Dijon

Open in trial search

Gastrointestinal stromal tumour

Recruiting

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Imatinib Mesilate
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Neoplasm

Recruiting

Phase 1/2 Study of ter-2013-01, imlunestrant, and fulvestrant in patients with solid tumors with AKT/PI3K/PTEN pathway alterations

Registered drugNo placebo

Phase 1/2 Study of ter-2013-01, imlunestrant, and fulvestrant in patients with solid tumors with AKT/PI3K/PTEN pathway alterations

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Fulvestrant

Contact Research Centre

Pancreatic carcinoma metastatic

Recruiting

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Gemcitabine
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Osteosarcoma

Recruiting

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cabozantinib
Sponsor:Institut Gustave Roussy

Contact Research Centre

Neoplasm

Recruiting

Study of BMS-986504 alone or in drug combination in adults with advanced or metastatic solid tumors with MTAP deletion

Registered drugNo placebo

Study of BMS-986504 alone or in drug combination in adults with advanced or metastatic solid tumors with MTAP deletion

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Ovarian cancer recurrent

Recruiting

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Genmab A/S

Contact Research Centre

Systemic lupus erythematosus+3

Recruiting

A Phase 3 Study of Enpatoran to Treat Active Cutaneous Lupus in Patients With or Without Systemic Disease

Investigational

A Phase 3 Study of Enpatoran to Treat Active Cutaneous Lupus in Patients With or Without Systemic Disease

Investigational

France

Participants:18–64 years · 65+ years
Sponsor:Merck Healthcare KGaA

Contact Research Centre

Colorectal cancer+2

Recruiting

Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

Registered drugNo placebo

Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Pancreatic carcinoma metastatic

Recruiting

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Incyte Corp.

Contact Research Centre

Follicular lymphoma

Recruiting

Study of MK-1045 plus rituximab in patients with newly diagnosed follicular lymphoma

Registered drugNo placebo

Study of MK-1045 plus rituximab in patients with newly diagnosed follicular lymphoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Age-related macular degeneration

Recruiting

A Phase 2/3 Study of intravitreal mk-8748 versus aflibercept in adults with neovascular age‑related macular degeneration

Registered drugNo placebo

A Phase 2/3 Study of intravitreal mk-8748 versus aflibercept in adults with neovascular age‑related macular degeneration

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Aflibercept
Sponsor:Eyebiotech Limited

Contact Research Centre

Non-Hodgkin's lymphoma

Recruiting

Study of MK-1045 alone or with tocilizumab in patients with Non‑Hodgkin Lymphoma to evaluate safety and efficacy

Registered drugNo placebo

Study of MK-1045 alone or with tocilizumab in patients with Non‑Hodgkin Lymphoma to evaluate safety and efficacy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Tocilizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Dijon

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for head and neck cancer, gastric cancer, and multiple types of lung cancer. Research encompasses novel therapeutic approaches and targeted treatments.

Head & Neck Squamous Cell Carcinoma
Pancreatic Ductal Adenocarcinoma
Non-Small Cell Lung Cancer

Several studies are evaluating new combination therapies and immunotherapy approaches for better treatment outcomes.

02 Immunology & Infectious Diseases

Research focusing on immune system responses and vaccine development, with particular emphasis on COVID-19 prevention and treatment strategies. Studies include innovative approaches to boosting immunity.

COVID-19 Vaccine Development
Immune System Enhancement
Preventive Medicine

Trials are investigating both intranasal and traditional vaccination methods for optimal immune response.

03 Cardiovascular Medicine

Studies focusing on heart disease management and prevention, including innovative treatments for acute myocardial infarction and heart failure prevention strategies.

Acute Myocardial Infarction
Heart Failure Prevention
Pain Management in Cardiac Conditions

Research includes novel pain management approaches and preventive treatments for cardiac conditions.

Back to France All countries